News

Rezo Therapeutics to Emerge from Stealth

January 27, 2023
The team behind Rezo Therapeutics, a new biotech co-founded by a group of University of California, San Francisco, scientists including Nevan Krogan, and industry veterans George Scangos and Norbert Bischofberger, was weighing if, and how, to finally come out of stealth mode after nearly five years...

Increasing the success potential of promising biotech companies

By Stephanie K. Marrus & John A. Blaho on January 19, 2023
Biotech startups benefit society by solving unmet scientific and medical needs, but more can be done to move their technologies to market more quickly. This month, Program Director Stephanie Marrus of the University of California, San Francisco's Global Entrepreneurship Program, together with John...

Catalyst Awardees Present to Investors at the “Born in California Investor Demo Days”

January 12, 2023
Several companies funded by the Catalyst Program and launched out of UCSF, including Alessa Therapeutics, Diatiro, Ooney, and Neomer Diagnostics, joined many of the University of California’s best and most investment-worthy startups seeking Seed and Series A investors, to pitch their business to...

ArsenalBio Announces First Patient Dosed in Phase 1 Clinical Trial in Treatment for Ovarian Cancer

January 06, 2023
Arsenal Biosciences, Inc., a clinical stage, programmable cell therapy company engineering advanced CAR T cell therapies for solid tumors, founded by UCSF Researchers Alex Marson, PhD, and Kole Roybal, PhD, today announced that the first patient has been dosed with AB-1015 in a Phase 1, first-in-...

Erasca Announces First Patient Dosed in HERKULES-1 Phase 1b Trial

December 22, 2022
Erasca, a clinical-stage precision oncology company co-founded by the University of California professor Kevan Shokat, and singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the dosing of their first...

Erasca Announces FDA Clearance of IND Application for CNS-Penetrant KRAS G12C Inhibitor

December 14, 2022
Erasca, a clinical-stage precision oncology company founded on UCSF professor Kevan Shokat's MedTech research, and focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the United States Food and Drug Administration has...

Vevo Therapeutics Launches with $12M Seed Financing

December 08, 2022
Mosaic drug discovery platform is the first to make in vivo data generation scalable, with single-cell precision; resulting datasets will be the world's largest atlas of how drugs interact with patient cells. This approach combines an atlas with AI models to capture in vivo context of disease early...

New Liquid Biopsy Detects Breast Cancer at Its Earliest Stages

December 07, 2022
Exai Bio and researchers at UCSF released data demonstrating that Exai’s novel, RNA-based liquid biopsy platform accurately detected breast cancer at the earliest stages and smallest tumor sizes. Earlier detection of breast cancer is crucial for optimal patient outcomes but cannot always be...

Rezo, Founded by Renowned UCSF Scientists, Launches with $78 Million

November 21, 2022
Rezo Therapeutics, a biotechnology company pioneering the integrated mapping of disease networks for precision therapeutics, launched today with $78 million from a Series A financing. The Series A financing was led by SR One, a16z Bio + Health, and Norwest Venture Partners, and also included SV...

How oncRNA Technology Could Revolutionize Cancer Diagnostics

November 14, 2022
An interview with Pat Arensdorf, co-founder and chief executive officer of Exai Bio, a biotech company founded on the scientific discoveries of UCSF's biochemistry professor Hani Goodarzi, PhD. MORE

Pages